Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Evalueer LAE102 bij gezonde proefpersonen en proefpersonen met overgewicht

10 november 2026 bijgewerkt door: Laekna Limited

Een gerandomiseerde, dubbelblinde, placebogecontroleerde, enkelvoudige en meervoudige dosis-escalatie fase I-studie om de veiligheid, verdraagbaarheid en farmacokinetiek van LAE102 bij gezonde proefpersonen en proefpersonen met overgewicht/obesitas te evalueren

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE102 injection in healthy and overweight/obese participants, and also evaluate the preliminary pharmacodynamic effect of multiple dose injections in overweight/obese participants.

Studie Overzicht

Gedetailleerde beschrijving

Part A is a randomized, double-blinded, placebo-controlled, single ascending dose by Intravenous (IV) administration in 40 Healthy participants;

Part B is a randomized, double-blinded, placebo-controlled, single ascending dose by subcutaneous (SC) administration in 24 Healthy participants;

Part C is a randomized, double-blind, placebo-controlled, multiple dose ascending and expanding by subcutaneous (SC) administration in 60 overweight/obese participants.

Studietype

Ingrijpend

Inschrijving (Geschat)

160

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 201203
        • Fudan Zhongshan Hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 65 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Male or female and aged 18 to 65 years (inclusive) at the screening visit
  2. Male Body weight ≥ 50 kg, female Body weight ≥ 45 kg. For Part A&B, 18.5 ≤ BMI ≤ 28 kg/m². For part C, 26.0 ≤ BMI ≤ 40.0 kg/m²
  3. Negative for human immunodeficiency virus antibody (HIV-Ab).
  4. Female subjects with no childbearing potential or with childbearing potential which serum human chorionic gonadotropin (hCG) test must <5mIU/mL .
  5. Male subjects are not allowed to donate sperm during this trial.
  6. Voluntarily participate in the study and provide a signed and dated informed consent form.
  7. Willing to comply with the scheduled visits, study treatment, laboratory tests, and other study-related procedures and requirements as stipulated in the study protocol.

Exclusion Criteria:

  1. With clinically significant abnormalities in vital signs, physical examination, ECG or laboratory test results specified in the protocol.
  2. Allergy to the investigational drug or its excipients, or a history of severe allergy (including any food or drug allergies).
  3. Self-reported weight change is more than 5% in the previous 3 months prior to screening.
  4. Diagnosed with secondary overweight or obesity.
  5. Any clinically significant medical conditions and any diseases affecting the safety of the subject or the determination of study results.
  6. History of major diseases or physical conditions in the central nervous system, respiratory system, cardiovascular system, digestive system, blood system, endocrine system, musculoskeletal diseases, mental illness, urinary system, or tumors, or any existing acute diseases, or other diseases or physical conditions that may affect the study or pose an unacceptable risk to the subjects.
  7. Positive for hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCV-Ab), or syphilis spirochete antibody (TP-Ab).
  8. Known or suspected history of substance abuse or positive drug screening test.
  9. Alcohol abuse within 1 year before screening or positive alcohol breath test at baseline.
  10. Smoking more than 5 cigarettes per day within 3 months before screening, or unable to comply with the prohibition of smoking during the study period.
  11. Received any vaccine within 30 days prior to screening, or planned to receive any vaccine during the study period.
  12. Inability to ensure no use of any drugs, including prescription and non-prescription drugs (excluding paracetamol, ibuprofen, and topically applied eye/nasal drops and ointments with no systemic exposure risk), vitamins, supplements and herbal medicines, from 14 days before the initial administration (if the half-life of the drug used exceeds 14 days, then 5 half-lives shall apply) until the last visit period.
  13. Participated in any clinical trial and received an investigational medicine or medical device within 3 months prior to dosing of the investigational product.
  14. Underwent major surgery within 30 days before the initial administration or planned to undergo major surgery during the study period.
  15. Donated blood or experienced blood loss ≥400 mL within 3 months before screening or received a blood transfusion.
  16. Have special dietary requirements and cannot comply with a standardized diet.
  17. History of fainting or syncope.
  18. Dieting or receiving weight loss treatment within 30 days before the initial administration or experiencing major changes in lifestyle.
  19. Use of GLP-1 receptor agonists, or weight loss medications or systemic corticosteroids (oral or intravenous for more than 7 days), or psychiatric medications within 3 months prior to the initial administration. Applicable to part C.
  20. Regular engaged in muscle strength related exercise, applicable to part C.
  21. Other situation that the investigator considers not appropriate.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Part A LAE102 IV

Single dose LAE102 by IV administration

A single dose of LAE102 administered intravenously

Andere namen:
  • Lae102 iv
Placebo-vergelijker: Part A placebo IV

Single dose placebo by IV administration

A single dose of placebo administered intravenously

Andere namen:
  • Placebo IV
Experimenteel: Part B LAE102 SC

Single dose LAE102 by SC administration

Single dose of LAE102 administered subcutaneously

Andere namen:
  • Lae102 SC
Placebo-vergelijker: Part B placebo SC

Single dose placebo by SC administration

single dose of placebo administered subcutaneously

Andere namen:
  • Placebo sc
Experimenteel: Part C LAE102 SC

Multiple dose LAE102 by SC administration

Multiple dose of LAE102 administered subcutaneously

Andere namen:
  • Lae102 SC
Placebo-vergelijker: Part C placebo SC

Multiple dose placebo by SC administration

Multiple dose of placebo administered subcutaneously

Andere namen:
  • Placebo sc

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number & severity of participants with treatment-related adverse events as assessed by CTCAE V5.0
Tijdsspanne: From Day 1 to Day 29 for single dose part. From Day 1 to Day 196 for multiple dose part

Findings on physical examination, ECG, vital signs, and reports of the laboratory results based on the CTCAE v5.0

From Day 1 to Day 29 for single dose part. From Day 1 to Day 196 for multiple dose part

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
characterize the peak of serum concentration (Cmax) of LAE102 injection in healthy subjects
Tijdsspanne: From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.

For both intravenously guttae & subcutaneous injection, to evaluate the maximum observed serum concentration(Cmax)

From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
characterize the area under the serum concentration versus time curve (AUC) of LAE102 injection in healthy subjects
Tijdsspanne: From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.

For both intravenously guttae & subcutaneous injection, to evaluate the area under the serum concentration versus time curve (AUC)

From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
evaluate the expression levels of Activin A in blood samples
Tijdsspanne: From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.

The validated methodology was employed to assay serum levels of Activin A in biological samples.

From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
Incidence of positive Anti-drug antibody(ADA) after administration
Tijdsspanne: pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.

Test ADA status in biological sample via validated methodology

pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Preliminary pharmacodynamic of total body weight for multiple dose part
Tijdsspanne: From pre-dose to Day 168.

Changes and percentage changes in total body weight (kg) after administration

From pre-dose to Day 168.
Preliminary pharmacodynamic of lean mass for multiple dose part
Tijdsspanne: From pre-dose to Day 168.

Changes and percentage changes in lean mass after administration

From pre-dose to Day 168.
Preliminary pharmacodynamic of fat mass for multiple dose part
Tijdsspanne: From pre-dose to Day 168.

Changes and percentage changes in fat mass after administration

From pre-dose to Day 168.
Preliminary pharmacodynamic of thigh muscle volume for multiple dose part
Tijdsspanne: From pre-dose to Day 168

Changes and percentage changes in thigh muscle volume after administration

From pre-dose to Day 168
Preliminary pharmacodynamic of bone mineral density(BMD) for multiple dose part
Tijdsspanne: From pre-dose to Day 168

Changes and percentage changes in BMD after administration

From pre-dose to Day 168
BMI/waist circumference change and percentage.
Tijdsspanne: From pre-dose to Day 29 forsingle dose. From pre-dose to Day 196 for multiple dose.

Assess the Body Mass Index (BMI)/waist circumference change and percentage.

From pre-dose to Day 29 forsingle dose. From pre-dose to Day 196 for multiple dose.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Hoofdonderzoeker: Xuening Li, Professor, Zhongshan hospital affiliated to Fundan University

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

25 juni 2024

Primaire voltooiing (Geschat)

30 juni 2027

Studie voltooiing (Geschat)

30 december 2027

Studieregistratiedata

Eerst ingediend

3 juni 2024

Eerst ingediend dat voldeed aan de QC-criteria

2 juli 2024

Eerst geplaatst (Werkelijk)

9 juli 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

12 november 2026

Laatste update ingediend die voldeed aan QC-criteria

10 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren